Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral dapsone for refractory rosacea
ChiCTR2600128386Phase 4Completed
- Sponsor
- The Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- Jul 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dapsone in rosacea (2 arms), sponsored by The Second Affiliated Hospital of Xi'an Jiaotong University. Primary endpoints: Investigator’s global assessment (IGA) and Clinician’s erythema assessment (CEA). Started Jul 2026; status: completed.
02
Drugs
dapsone
03
Conditions
rosacea
Beyond the preview
Go deeper on ChiCTR2600128386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128386.